- cafead Aug 11, 2020 at 11:42: AM
via Seres Therapeutics has endured a tough few years of trials setbacks, cuts and new management, but the GI biotech is hoping with its new set of broadly positive late-stage data it can finally file for an approval.
The Cambridge, Massachusetts-based biotech said Monday morning that its pivotal phase 3 test, known as ECOSPOR III, which was testing its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI) came through.
article source
The Cambridge, Massachusetts-based biotech said Monday morning that its pivotal phase 3 test, known as ECOSPOR III, which was testing its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI) came through.
article source